Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting ...

Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers NEW YORK, (GLOBE NEWSWIRE) ...

Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24th, 1:39-1:45 p.m. PST (instead of Tuesday, February 25th, 1:00-1:45 p.m. PST).

Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in ...

GeneCker showcases MUTE-Seq gene editing technology for cancer detection at AACR Biotechnology firm GeneCker to unveil ...

For more information about the conference, please visit the event website. About Sonnet BioTherapeutics Holdings, Inc. Sonnet is an oncology-focused biotechnology company with a proprietary platform ...

Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

Sonnet BioTherapeutics Holdings, Inc. announced that its abstract has been accepted for a poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference, scheduled ...

For a full list of posters and presentation details, visit Champions Oncology at AACR 2025. To schedule a meeting with the Champions team during AACR 2025, please visit the same link. Champions ...

For more information about the conference, please visit the event website . About Sonnet BioTherapeutics Holdings, Inc. Sonnet is an oncology-focused biotechnology company with a proprietary ...